Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinical outcomes of pharmacokinetic and pharmacodynamic meropenem dosing in critically ill patients with sepsis or septic shock
TCTR20220106001Phase 3Recruiting
- Sponsor
- Silpakorn University
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of meropenem in sepsis, septic shock, sponsored by Silpakorn University. Started Jan 2022; status: recruiting.
02
Drugs
meropenem
03
Conditions
sepsisseptic shock
Beyond the preview
Go deeper on TCTR20220106001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20220106001.